Valneva Says Single-Dose Chikungunya Vaccine IXCHIQ Showed Antibody Persistence Consistent With Prior Results, In Line With Company Expectations, With 94% Seroresponse At Year 5 Across Age Groups

Benzinga
Open on Benzinga